Long-term results of autologous hematopoietic stem-cell transplantation after high-dose90Y-ibritumomab tiuxetan for patients with poor-risk non-Hodgkin lymphoma not eligible for high-dose BEAM

Journal of Clinical Oncology

Volumn 31, Issue 23, 2013, Pages 2974-2976

  Devizzi, Liliana ^a   Guidetti, Anna ^a   Seregni, Ettore ^a   Passera, Roberto ^b   Maccauro, Marco ^a   Magni, Michele ^a   Testi, Adele ^a   Di Nicola, Massimo ^a   Tarella, Corrado ^c   Matteucci, Paola ^a   Viviani, Simonetta ^a   Ruella, Marco ^c   Carlo Stella, Carmelo ^d,e   Chiesa, Carlo ^a   Cox, Maria Cristina ^f   Bombardieri, Emilio ^a   Gianni, Alessandro M ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c MAURIZIANO HOSPITAL   (Italy)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYTARABINE; ETOPOSIDE; IBRITUMOMAB TIUXETAN; MELPHALAN; RITUXIMAB;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CONSOLIDATION CHEMOTHERAPY; DRUG MEGADOSE; HUMAN; LETTER; MANTLE CELL LYMPHOMA; MOLECULAR PROBE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PANCYTOPENIA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY;

ANTIBODIES, MONOCLONAL; DISEASE-FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, NON-HODGKIN; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; RISK FACTORS; TRANSPLANTATION, AUTOLOGOUS; YTTRIUM RADIOISOTOPES;

EID: 84889785361     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.2922     Document Type: Letter

References (17)

1. Devizzi L, Guidetti A, Tarella C, et al: High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: An outpatient preparative regimen for autologous hematopoietic cell transplantation. J Clin Oncol 26:5175-5182, 2008
2. Witzig TE, Flinn IW, Gordon LI, et al: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20:3262-3269, 2002
3. Gordon LI, Molina A, Witzig T, et al: Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 study. Blood 103:4429-4431, 2004
4. Gordon LI, Witzig T, Molina A, et al: Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma 5:98-101, 2004
5. Schilder R, Molina A, Bartlett N, et al: Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm 19:478-481, 2004
6. Witzig TE, White CA, Gordon LI, et al: Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. J Clin Oncol 21:1263-1270, 2003
7. Emmanouilides C, Witzig TE, Wiseman GA, et al: Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma. Cancer Biother Radiopharm 22:684-691, 2007
8. Witzig TE, White CA, Wiseman GA, et al: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 17:3793-3803, 1999
9. Krishnan A, Nademanee A, Fung HC, et al: Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 26:90-95, 2008
10. Shimoni A, Zwas ST, Oksman Y, et al: Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. Exp Hematol 35:534-540, 2007
11. Shimoni A, Avivi I, Rowe JM, et al: A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer 118:4706-4714, 2012
12. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007
13. Magni M, Di Nicola M, Carlo-Stella C, et al: Efficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma: Long-term follow-up. Bone Marrow Transplant 45:1119-1120, 2010
14. Armitage JO, Carbone PP, Connors JM, et al: Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 21:897-906, 2003
15. Lenz G, Dreyling M, Schiegnitz E, et al: Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 22:4926-4933, 2004
16. Bhatia R, Van Heijzen K, Palmer A, et al: Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma. J Clin Oncol 23:6699-6711, 2005
17. Gisselbrecht C, Glass B, Mounier N, et al: Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28:4184-4190, 2010